je.st
news
Tag: iii
NERC Holds Grid Security and Incident Response GridEx III Exercise
2015-11-23 17:42:00| Transmission & Distribution World
On Nov.18-19, more than 350 organizations and 3,000 participants from across the electric utility industry and federal and state governments participated in the North American Reliability Corporation grid security read more
Tags: security
iii
response
exercise
Call of Duty: Black Ops III (for PlayStation 4)
2015-11-23 00:02:45| PC Magazine: New Product Reviews
For better or worse, Call of Duty: Black Ops 3 is exactly the straightforward big-budget shooter you expect, offering entertaining gunplay, a ridiculous (but fun) campaign, and deep online multiplayer with a bevy of game modes.
Call of Duty: Black Ops III (for PlayStation 4)
2015-11-20 22:59:46| PC Magazine: New Product Reviews
For better or worse, Call of Duty: Black Ops 3 is exactly the straightforward big-budget shooter you expect, offering entertaining gunplay, a ridiculous (but fun) campaign, and deep online multiplayer with a bevy of game modes.
Sharp Corporation Selects QuickLogic's ArcticLink III VX5 and PolarPro 3 for its RoBoHoN Mobile Robot Phone
2015-11-20 11:31:11| Industrial Newsroom - All News for Today
QuickLogic's ArcticLink III VX5 facilitates display bridging while optimizing display quality and lowering power consumption for pico projectors QuickLogic's PolarPro 3 in-system reprogrammable logic delivers twice the density of traditional FPGAs while consuming as little as 55 micro amps of static...
Tags: phone
mobile
iii
corporation
Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
2015-11-19 12:30:12| Merck.com - Research & Development News
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lillys ALIMTA (pemetrexed for injection) and Mercks KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Language: English read more
Sites : [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] next »